Literature DB >> 9582486

Gonorrhoea: auxotypes, serovars, and clinical manifestations among female sex workers from Kinshasa, Zaïre.

L Mukenge-Tshibaka1, M Alary, E Van Dyck, M Laga, N Nzila.   

Abstract

The main question in this paper was to look at the distribution of auxotypes and serovars of Neisseria gonorrhoeae and check whether they correlate with clinical symptoms/signs among female sex workers (FSW) from Kinshasa, Zaïre. The subject were 1233 FSW enrolled in a cross sectional study on STDs and HIV infection in 1988; 771 of them were followed prospectively for a median duration of 23 months. At each visit, clinical symptoms and signs of cervicitis were recorded and the subjects were screened for gonococcal and chlamydial infection. The pre-dominant auxotypes were prototrophic (35.2%), proline requiring (29.6%), and proline requiring phenylalanine inhibition (19%). Serovars 1A-6 (42.5%) and 1B-1 (16.7%) were the commonest. Infection with auxotype prototrophic and phenylalanine inhibition (Proto/Phenali) was significantly associated with both mucopurulent cervicitis and pelvic inflammatory disease; (OR = 8.9; p = 0.002 and OR =19 x9; p = 0.002; respectively). Despite the few associations found in this study, there was not clear pattern linking clinical manifestations to auxotype/serovar profiles.

Entities:  

Mesh:

Year:  1997        PMID: 9582486      PMCID: PMC1195950          DOI: 10.1136/sti.73.6.564

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  10 in total

1.  Auxanographic grouping and typing of Neisseria gonorrhoeae.

Authors:  A T Hendry; I O Stewart
Journal:  Can J Microbiol       Date:  1979-04       Impact factor: 2.419

2.  Gonorrhoea in heterosexual men. Correlation between gonococcal W serogroup, Chlamydia trachomatis infection and objective symptoms.

Authors:  A K Rudén; M Bäckman; S Bygdeman; A Jonsson; O Ringertz; E Sandström
Journal:  Acta Derm Venereol       Date:  1986       Impact factor: 4.437

3.  Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study.

Authors:  M Laga; A Manoka; M Kivuvu; B Malele; M Tuliza; N Nzila; J Goeman; F Behets; V Batter; M Alary
Journal:  AIDS       Date:  1993-01       Impact factor: 4.177

4.  Antibiotic susceptibility in relation to serogroup and auxotype of Neisseria gonorrhoeae isolates from Gabon.

Authors:  M F Peeters; E H Frost; S A Ossari; B Ivanoff
Journal:  Sex Transm Dis       Date:  1987 Jul-Sep       Impact factor: 2.830

5.  Epidemiology of gonorrhea: distribution and temporal changes in auxotype/serovar classes of Neisseria gonorrhoeae.

Authors:  J S Knapp; K K Holmes; P Bonin; E W Hook
Journal:  Sex Transm Dis       Date:  1987 Jan-Mar       Impact factor: 2.830

6.  Serological classification of Neisseria gonorrhoeae with use of monoclonal antibodies to gonococcal outer membrane protein I.

Authors:  J S Knapp; M R Tam; R C Nowinski; K K Holmes; E G Sandström
Journal:  J Infect Dis       Date:  1984-07       Impact factor: 5.226

7.  Gonorrhea in women prostitutes: clinical data and auxotypes, serovars, plasmid contents of PPNG, and susceptibility profiles.

Authors:  F Vázquez; V Palacio; J A Vázquez; S Berrón; A González; J J Llaneza
Journal:  Sex Transm Dis       Date:  1991 Jan-Mar       Impact factor: 2.830

8.  Correlation of auxotype and protein I type with expression of disease due to Neisseria gonorrhoeae.

Authors:  R C Brunham; F Plummer; L Slaney; F Rand; W DeWitt
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

9.  Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection.

Authors:  F A Plummer; J N Simonsen; H Chubb; L Slaney; J Kimata; M Bosire; J O Ndinya-Achola; E N Ngugi
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

10.  Changes in the prevalence of auxotypes of Neisseria gonorrhoeae among black and white patients attending a clinic for sexually transmitted diseases.

Authors:  R C Noble; M C Parekh
Journal:  Sex Transm Dis       Date:  1983 Jan-Mar       Impact factor: 2.830

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.